These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29362902)

  • 1. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.
    Shabason JE; Chen J; Apisarnthanarax S; Damjanov N; Giantonio B; Loaiza-Bonilla A; O'Dwyer PJ; O'Hara M; Reiss KA; Teitelbaum U; Wissel P; Drebin JA; Vollmer C; Kochman M; Mick R; Vergara N; Jhala N; Doucette A; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):609-614. PubMed ID: 29362902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
    Yamada S; Fujii T; Yokoyama Y; Kawashima H; Maeda O; Suzuki K; Okada T; Ono E; Yamaguchi J; Takano N; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Kodera Y
    Cancer Chemother Pharmacol; 2018 May; 81(5):815-821. PubMed ID: 29502139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer.
    Takahashi H; Akita H; Ioka T; Wada H; Tomokoni A; Asukai K; Ohue M; Yano M; Ishikawa O
    Pancreas; 2018 Oct; 47(9):1135-1141. PubMed ID: 30134354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
    Dorman K; Boeck S; Caca K; Reichert M; Ettrich TJ; Oettle H; Waidmann O; Modest DP; Müller L; Michl P; Kanzler S; Pink D; Reinacher-Schick A; Geißler M; Pelz H; Kunzmann V; Held S; Schichtl T; Heinemann V; Kullmann F
    Lancet Gastroenterol Hepatol; 2024 Oct; 9(10):935-943. PubMed ID: 39159648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
    Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
    Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
    Sai S; Toyoda M; Tobimatsu K; Satake H; Yasui H; Kimbara S; Koyama T; Fujishima Y; Imamura Y; Funakoshi Y; Kiyota N; Toyama H; Kodama Y; Minami H
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):65-71. PubMed ID: 33098471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
    Reni M; Balzano G; Zanon S; Passoni P; Nicoletti R; Arcidiacono PG; Pepe G; Doglioni C; Fugazza C; Ceraulo D; Falconi M; Gianni L
    Br J Cancer; 2016 Jul; 115(3):290-6. PubMed ID: 27404453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
    Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
    Arscott WT; Nead KT; Bear A; Venigalla S; Shabason J; Lukens JN; Plastaras JP; Wojcieszynski A; Metz J; O'Hara M; Reiss KA; Teitelbaum U; Loaiza-Bonilla A; Drebin J; Lee MK; Shroff SG; Ben-Josef E
    Am J Clin Oncol; 2021 Sep; 44(9):469-474. PubMed ID: 34310350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
    De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
    BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
    Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
    Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
    Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
    Dotan E; Cardin DB; Lenz HJ; Messersmith W; O'Neil B; Cohen SJ; Denlinger CS; Shahda S; Astsaturov I; Kapoun AM; Brachmann RK; Uttamsingh S; Stagg RJ; Weekes C
    Clin Cancer Res; 2020 Oct; 26(20):5348-5357. PubMed ID: 32694153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
    Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB
    Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
    Kim H; Olsen JR; Green OL; Chin RI; Hawkins WG; Fields RC; Hammill C; Doyle MB; Chapman W; Suresh R; Tan B; Pedersen K; Jansen B; DeWees TA; Lu E; Henke LE; Badiyan S; Parikh PJ; Roach MC; Wang-Gillam A; Lim KH
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):214-223. PubMed ID: 35878713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.